Law360, Washington (May 04, 2012, 8:09 PM ET) -- Despite a recent appellate ruling blessing pay-for-delay settlements that stay within the scope of the contested patent, the head of the Federal Trade Commission's health care unit warned Friday that the agency would not be dissuaded from challenging the deals between generic- and brand-drug makers.
Both Markus H. Meier, the FTC's assistant director for health care services and products, and its chairman, Jon Leibowitz, reaffirmed the priority the agency places on the settlements at an American Bar Association conference on antitrust in the health care industry...
FTC 'Still In The Game' On Pay-For-Delay Challenges
To view the full article, take a free trial now.
